Skip to main content

Table 4 Analysis of the impact of cardiovascular risk factors on the biomarkers of cellular and plasma hypercoagulability in patients with breast cancer

From: Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

  Total population of patients (n = 62)
  CV RF (n = 21) No CV RF (n = 41)
MRI (mM/min) 134 ± 51 167 ± 51
Peak (nM) 317 ± 89 357 ± 72
ETP (mM.min) 1490 ± 346 1552 ± 335
Pd-MP (/μL) 8133 ± 6480 10955 ± 8893
Pd-MP/PS + (/μL) 7896 ± 6328 10599 ± 8552
PPL (sec) 42 ± 10 44 ± 11
D-dimers (ng/ml) 1190 ± [440–1750] 540 ± [280–830]
  1. CV RF: Cardiovascular risk factors.
  2. Pd-MP: Platelet derived microparticles.
  3. Pd-MP/PS+: Platelet derived microparticles expressing phosphatidylserin.
  4. PPL: Procoagulant phospholipid dépendent clotting time.
  5. MRI: Mean rate index of the propagation phase.
  6. ETP: Endogenous thrombin generation.
  7. *p = 0,05 versus No CV RF.